KEGG: cel:CELE_ZK381.2
UniGene: Cel.11610
ZK381.2 is closely related to the open reading frame ZK381.1, which corresponds to the him-3 locus in Caenorhabditis elegans. The HIM-3 protein is a meiosis-specific component of chromosome cores with approximately 16% identity and 31% similarity to the amino-terminal portion of the yeast lateral element protein Hop1p . HIM-3 is a 291-amino-acid polypeptide with a predicted molecular mass of 33.1 kD that plays essential roles in chromosome synapsis and chiasma formation during meiosis .
Based on research with similar antibodies, ZK381.2/HIM-3 antibodies are primarily used for:
Immunolocalization of proteins on meiotic chromosomes
Western blot analysis of protein expression and modification
Chromatin immunoprecipitation (ChIP) to study protein-DNA interactions
Immunoprecipitation to identify protein-protein interactions
Cytological analysis of meiotic progression
Antibodies raised against HIM-3 have been successfully used to localize the protein to condensing chromosomes in early prophase I and to the cores of both synapsed and desynapsed chromosomes .
For optimal results with ZK381.2 antibody applications, researchers should consider:
Tissue Fixation and Preparation:
For immunohistochemistry: 4% paraformaldehyde fixation for preserved morphology
For Western blotting: Sample preparation in 1x PBS buffer with protease inhibitors
For immunoprecipitation: Gentle lysis conditions to maintain protein interactions
Protein Extraction Protocol:
Homogenize C. elegans samples in appropriate buffer (e.g., RIPA buffer)
Include protease inhibitors to prevent degradation
Centrifuge to remove debris
Quantify protein concentration before proceeding with applications
Similar to other research antibodies, purified antibodies are typically supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose for stability .
Comprehensive validation of ZK381.2 antibodies should include:
Recommended Validation Steps:
Western blot analysis with positive and negative controls
Immunostaining patterns compared with known localization data
RNA interference (RNAi) depletion controls to confirm specificity
Testing on mutant strains lacking the target protein
Pre-absorption with immunizing peptide to confirm specificity
In previous studies with meiotic proteins, chromosomes appeared to condense normally in the absence of detectable protein after RNAi treatment, providing a useful negative control . Testing antibodies against tissues from knockout organisms provides the most stringent specificity control.
When designing ChIP experiments with ZK381.2 antibodies, researchers should include:
| Control Type | Purpose | Implementation |
|---|---|---|
| Input Control | Normalize for DNA amount | Reserve 5-10% of chromatin before immunoprecipitation |
| No Antibody Control | Detect non-specific binding | Perform IP procedure without antibody |
| IgG Control | Measure background | Use same amount of non-specific IgG |
| Positive Control | Verify technique | Target known binding sites or proteins |
| Negative Control | Verify specificity | Use primers for regions not expected to bind |
Additionally, researchers should perform immunoprecipitation with an unrelated antibody from the same species to rule out non-specific binding due to the host species.
ZK381.2/HIM-3 antibodies provide powerful tools for studying meiotic processes:
Advanced Applications:
Temporal profiling of protein localization: Track HIM-3 localization through meiotic stages
Co-immunoprecipitation: Identify interaction partners at different meiotic stages
Super-resolution microscopy: Analyze detailed chromosome core structures
ChIP-seq analysis: Map genome-wide binding patterns
In conjunction with live imaging: Correlate fixed and live cell observations
Research demonstrates that HIM-3 localizes to condensing chromosomes in early prophase I and remains associated with chromosome cores throughout synapsis and desynapsis , making antibodies against this protein valuable for studying meiotic progression.
When designing multiplexed immunostaining experiments:
Critical Factors:
Antibody compatibility: Ensure primary antibodies originate from different host species
Fluorophore selection: Choose fluorophores with minimal spectral overlap
Sequential staining: Consider sequential staining when using antibodies from the same species
Blocking optimization: Adjust blocking conditions to minimize cross-reactivity
Controls: Include single-antibody controls to assess bleed-through
For example, when combining antibodies against HIM-3 and synaptonemal complex proteins, researchers should carefully select antibodies raised in different host species (e.g., rabbit anti-HIM-3 and mouse anti-SYP-1) to allow clear discrimination with species-specific secondary antibodies.
Analysis of ZK381.2/HIM-3 localization patterns in meiotic mutants requires careful consideration:
Normal pattern: HIM-3 localizes to chromosome cores during early prophase and remains associated through synapsis and desynapsis
Interpretation of alterations:
Absence of localization may indicate upstream defects in chromosome condensation
Discontinuous localization suggests altered chromosome organization
Persistent localization in late prophase might indicate defects in protein removal
Comparisons with wild-type controls: Always process mutant and wild-type samples in parallel
Quantification approaches: Consider quantitative analysis of signal intensity and distribution
In previous studies, hypomorphic him-3 mutants show severe defects in chromosome segregation despite being proficient in synapsis , highlighting the importance of careful phenotypic interpretation.
Researchers frequently encounter these challenges:
| Issue | Possible Causes | Solutions |
|---|---|---|
| High background | Insufficient blocking, antibody concentration too high | Optimize blocking conditions, titrate antibody, use highly specific affinity-purified antibodies |
| No signal | Epitope masking, inadequate fixation | Try multiple fixation methods, include antigen retrieval steps |
| Non-specific bands | Cross-reactivity, protein degradation | Use affinity-purified antibodies, include protease inhibitors |
| Variable results | Batch effects, inconsistent fixation | Standardize protocols, use internal controls |
| Inconsistent IP results | Buffer incompatibility, weak antibody-antigen interaction | Optimize IP conditions, crosslink if necessary |
When troubleshooting, researchers should consider that antibodies perform differently across applications. For example, an antibody that works well for Western blotting may fail in immunoprecipitation due to conformational requirements.
To distinguish specific from non-specific signals:
Compare with known localization patterns: HIM-3 should localize to chromosome cores in meiotic nuclei
Use genetic controls: Test antibody staining in him-3 mutants or RNAi-depleted samples
Perform peptide competition assays: Pre-incubate antibody with immunizing peptide
Compare multiple antibodies: If available, use antibodies targeting different epitopes
Correlate with functional data: Specific signals should correlate with known protein function
Researchers should be particularly cautious when interpreting signals in tissues where the protein is not expected to be expressed or when signals appear in cellular compartments inconsistent with known localization patterns.
When faced with contradictory results:
Comprehensive validation: Re-validate each antibody using the methods described in question 2.1
Epitope mapping: Determine the exact epitopes recognized by each antibody
Post-translational modification analysis: Consider whether modifications affect epitope recognition
Isoform specificity: Determine whether antibodies recognize different protein isoforms
Orthogonal approaches: Use alternative methods (e.g., tagged proteins) to confirm results
For example, antibodies targeting different regions of a protein may give different results if:
One epitope is masked in certain protein complexes
Post-translational modifications alter epitope accessibility
Protein undergoes conformational changes in different cellular contexts
ZK381.2/HIM-3 antibodies offer valuable tools for comparative studies:
Cross-species reactivity testing: Examine conservation across nematode species
Comparative localization studies: Compare chromosomal localization patterns across species
Functional complementation: Combine with transgenic studies expressing orthologs
Co-evolution analysis: Study interaction partners across species
The HIM-3 protein shares 16% identity and 31% similarity with the amino-terminal portion of yeast Hop1p , suggesting evolutionary conservation of chromosome core components that could be further explored with appropriate antibodies.
Integration of ZK381.2 antibodies with cutting-edge microscopy offers new research opportunities:
Super-resolution microscopy (SRM): Resolve fine structural details of chromosome cores
Expansion microscopy: Physically expand samples to increase effective resolution
Correlative light and electron microscopy (CLEM): Combine fluorescence and ultrastructural data
Single-molecule localization: Precisely map protein distribution within chromosome structures
Live-cell and fixed-cell correlation: Use antibodies to validate live imaging with fluorescent tags
These approaches could provide unprecedented insights into meiotic chromosome organization and dynamics beyond what conventional microscopy reveals.
ZK381.2/HIM-3 antibodies could contribute to disease-related research:
Meiotic defect models: Study chromosome segregation errors relevant to human aneuploidy
DNA repair pathway analysis: Examine relationships between chromosome cores and repair mechanisms
Cancer research applications: Investigate meiotic proteins aberrantly expressed in cancers
Aging studies: Explore age-related changes in meiotic chromosome dynamics
Reproductive biology: Analyze impacts of environmental factors on meiotic progression
Understanding meiotic chromosome dynamics has direct relevance to human reproductive health, and antibody tools for studying conserved components like HIM-3 could provide valuable insights into disease mechanisms.